Diabetes prevalence and management patterns in US adults, 2001–2023
Acta Diabetologica · 2025
DOI: 10.1007/s00592-025-02572-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Diabetologica, 2025. Verfasst von Miaojin Hu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Diabetes is a leading cause of morbidity and mortality in the United States. We aimed to characterize secular trends in diabetes prevalence, control of glucose and associated comorbidities, and medication use.
Methods
This was a retrospective analysis of National Health and Nutrition Examination Series data from 2001 to 2023. We focused on three outcomes: (1) prevalence of diabetes defined by known diagnosis, hemoglobin A1c ≥ 6.5%, or fasting glucose ≥ 126 mg/dL, and among individuals with diabetes (2) control of glucose levels, low-density lipoprotein, and blood pressure and (3) medication therapy. Predictors were cycle (year) and demographics, specifically age, sex, race/ethnicity, educational level, and household income.
Results
We included 27,437 participants of whom 3467 had diagnosed diabetes and an additional 1602 had undiagnosed diabetes. Diabetes prevalence increased from 10.0% in 2001–2002 to 15.1% in 2021–2023 and was higher in men versus women, and Hispanic/Latino or non-Hispanic Black vs. non-Hispanic White participants. Glycemic control declined over time, from 61.5 to 44.9% having hemoglobin A1c < 7% in 2001–2002 vs. 2021–2023; control was lower in younger participants and those with lower educational attainment. Lipid control improved over time but remained poor: 73.1% had low-density lipoprotein ≥ 70 mg/dL in 2017–2020, and only half of these individuals were taking a statin. There were no significant changes over time in blood pressure control, with 44–56% having blood pressure ≥ 130/80 mmHg. Other than lower lipid control in women, we did not observe differences in control of lipids or blood pressure, or in medication treatment, based on sex and race/ethnicity.
Discussion
Diabetes has increased in prevalence from 2001 to 2023 and management of hyperglycemia and associated risk factors remains inadequate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA.
- Robert Larner MD College of Medicine, University of Vermont, Burlington, VT, USA.
- Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
- Department of Medicine, Division of Gastroenterology and Hepatology, University of Arizona College of Medicine, Phoenix, AZ, USA.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
- Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University, Stanford, CA, USA.
Zitieren
APA
Hu, M., Le, M. H., Yeo, Y. H., Wijarnpreecha, K., Likhitsup, A., Kim, D., & Chen, V. L. (2025). Diabetes prevalence and management patterns in US adults, 2001–2023. Acta Diabetologica. https://doi.org/10.1007/s00592-025-02572-6
Vancouver
Hu M, Le MH, Yeo YH, Wijarnpreecha K, Likhitsup A, Kim D, et al. Diabetes prevalence and management patterns in US adults, 2001–2023. Acta Diabetologica. 2025. doi:10.1007/s00592-025-02572-6
BibTeX
@article{Hu2025,
author = {Hu, Miaojin and Le, Michael H and Yeo, Yee Hui and Wijarnpreecha, Karn and Likhitsup, Alisa and Kim, Donghee and Chen, Vincent L},
title = {Diabetes prevalence and management patterns in US adults, 2001–2023},
journal = {Acta Diabetologica},
year = {2025},
doi = {10.1007/s00592-025-02572-6}
}
EUVIMED